天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第三季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - For the six months ended June 30, 2023, the group achieved a total revenue of RMB 185,915,928, a decrease of 9.40% compared to RMB 205,210,475 for the same period in 2022[4] - The gross profit for the same period was RMB 6,848,825, representing a decline of 33.96% from RMB 10,370,957 in the previous year[4] - The loss attributable to equity holders of the company was RMB 11,250,040, an improvement from a loss of RMB 13,248,062 in the prior year[4] - The basic loss per share for the period was RMB 0.594, compared to RMB 0.699 for the same period last year[4] - The company's comprehensive gross profit for the same period was RMB 6,848,825, a year-on-year decrease of 33.96% from RMB 10,370,957 in 2022, resulting in a gross profit margin of 3.68% compared to 5.05% in the previous year[32] Assets and Liabilities - The total assets as of June 30, 2023, amounted to RMB 326,577,334, down from RMB 337,196,239 at the end of 2022[6] - Current liabilities totaled RMB 221,585,923, compared to RMB 218,249,273 at the end of 2022, indicating a slight increase[7] - The net asset value of the company was RMB 69,757,798, a decrease from RMB 83,713,353 at the end of the previous year[7] - The net receivables from trade accounts as of June 30, 2023, were RMB 20,359,441, down from RMB 31,866,638 as of December 31, 2022, reflecting a decrease of 36.1%[19] - The company's prepayments and other receivables totaled RMB 61,312,181 as of June 30, 2023, down from RMB 77,654,553 as of December 31, 2022, a decrease of 21.1%[20] - The group's debt-to-asset ratio was 0.79 as of June 30, 2023, compared to 0.75 as of December 31, 2022[38] Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2023, was RMB 3,102,287, compared to a cash outflow of RMB 18,428,270 in the same period of 2022[6] - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,288,270, compared to RMB 3,198,037 in the same period of 2022, indicating a decrease of 59.7%[6] - The company invested approximately RMB 461,949 in property, plant, and equipment during the period, significantly lower than RMB 1,428,453 in the same period of 2022[17] Expenses - Research and development expenses for the period were RMB 13,773,232, compared to RMB 12,242,150 in the previous year, indicating increased investment in R&D[5] - The company's income tax expense for the six months ended June 30, 2023, was RMB -41,394, compared to RMB 146,275 in the same period of 2022, indicating a reduction in tax liability[14] - The group's sales and distribution costs for the six months ended June 30, 2023, were RMB 5,277,328, a decrease of 35.00% compared to RMB 8,118,740 for the same period in 2022[33] - Research and administrative expenses increased by 12.51% to RMB 13,773,232 for the six months ended June 30, 2023, compared to RMB 12,242,150 in the same period of 2022[34] - Financing costs decreased by 54.32% to RMB 1,521,452 for the six months ended June 30, 2023, down from RMB 3,330,598 in the same period of 2022[35] Dividends - The company did not recommend the payment of any dividend for the six months ended June 30, 2023[4] - The company has not proposed an interim dividend for the six months ended June 30, 2023, consistent with no dividend declared for the same period in 2022[26] - The company did not declare any interim dividend for the six months ending June 30, 2023[58] Business Operations - The company is involved in two main business areas: bio-composite fertilizers and elderly care services, focusing on the integration of medical and elderly care services[28] - The company has strengthened its market sales management and adjusted product structure in response to market conditions, aiming to stabilize its bio-composite fertilizer business[29] - The company has expanded its elderly health resource allocation business, including the rental of assistive devices and the sale of elderly food products[31] - The aging population in China, with 280 million people aged 60 and above, presents significant opportunities for the elderly care services sector, which the group aims to develop further[43] - The group has developed elderly health resource allocation services, including assistive device rentals and elderly food sales, with plans to expand into more categories[43] Governance and Management - The audit committee reviewed the interim results and report for the six months ending June 30, 2023[52] - No new share option schemes were approved during the first half of 2023[53] - The company did not purchase, sell, or redeem any of its shares during the review period[56] - The company has not entered into any management contracts for its overall business or any major business during the first half of 2023[54] - The board of directors and management are committed to implementing the corporate governance code as per GEM listing rules[57] - There were no reported conflicts of interest or competition with the company's business as of June 30, 2023[50] - The company is currently led by co-CEOs Sun Li and Qin Wenhua, with Sun also serving as the chairperson[57] - The company maintains a focus on transparency and effective internal controls in its governance practices[57] Shareholder Information - As of June 30, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%)[48]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年半年度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所《 證券上市規則》（「 上市規則」）而刊載，旨在提供有關天 津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司的董事願就 ...

Financial Performance - For the three months ended March 31, 2023, the group achieved a total revenue of RMB 86,420,934, a decrease of 3.11% compared to RMB 89,195,530 for the same period last year[3] - The gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 in the previous year[3] - The loss attributable to equity holders of the company was RMB 5,876,609, slightly improved from a loss of RMB 6,043,544 in the same period last year, resulting in a basic loss per share of RMB 0.310 compared to RMB 0.319[3] - The revenue from fertilizer products was RMB 86,245,207, down from RMB 89,086,907 in the previous year, while revenue from elderly care and health services increased to RMB 175,727 from RMB 108,623[6] - The group reported a pre-tax loss of RMB 7,706,292, compared to a loss of RMB 6,111,450 in the previous year[4] - The income tax expense for the period was RMB 724, compared to zero in the same period last year[8] - The company's gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 year-on-year, with a gross profit margin of 3.53%, down 2.62% from 6.15% in the previous year[14] Expenses and Costs - The group incurred research and administrative expenses of RMB 6,864,118, compared to RMB 6,621,896 in the previous year[4] - The financing costs for the period were RMB 781,536, an increase from RMB 742,591 in the same period last year[4] Dividends and Shareholder Information - The board of directors did not recommend the payment of dividends for the three months ended March 31, 2023[11] - The weighted average number of ordinary shares for calculating basic loss per share remained constant at 1,894,500,000 shares[10] - As of March 31, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., holding 182,500,000 shares (9.63% of issued share capital) and Shenzhen Xiangyong Investment Co., holding 180,000,000 shares (9.50%)[24] - The beneficial ownership structure includes significant stakes held by Xiangyong Investment and Guangdong Jiamei Ecological Technology Co., each holding 180,000,000 shares (9.50%)[24] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the group's performance for the first quarter ending March 31, 2023[27] - The company has adhered to all provisions of the Corporate Governance Code during the review period[31] - There were no arrangements made that would allow directors or their family members to profit from purchasing company shares during the review period[23] - The company reported no competitive interests from directors, supervisors, or management shareholders during the period ending March 31, 2023[26] Strategic Focus and Future Plans - The company is focusing on the bio-composite fertilizer business and elderly care services, targeting the growing elderly population in China, which reached 280 million (19.8% of the total population) by the end of 2022[19] - The company plans to enhance its marketing management and adjust product structures in response to market demand, aiming to improve market share in the composite fertilizer sector[18] - The company is exploring the development of elderly health resource allocation services, including the rental of assistive devices and sales of elderly food products, to create new profit growth points[19] Capital Structure and Financial Position - The company has not issued new shares during the reporting period, maintaining its existing capital structure[14] - The company did not approve any new share option plans during the period ending March 31, 2023[28] - The company did not repurchase any shares during the review period, nor did it purchase, sell, or redeem any shares[30] - The company has no contingent liabilities related to bank loans as of March 31, 2023, maintaining a stable financial position[15] - The company’s bank borrowings are denominated in RMB and are generally renewed annually upon maturity, indicating a conservative treasury policy[17] Industry Outlook - The composite fertilizer industry is expected to stabilize in terms of raw material prices due to supply-demand dynamics and policy adjustments, following a period of rapid development and subsequent industry adjustments[18]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第一季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 449.676 million, a decrease of 5.6% compared to RMB 476.385 million in 2021[13]. - The gross profit for the same period was RMB 16.395 million, resulting in a gross margin of 3.65%, down from 9.57% in 2021[13]. - The net loss attributable to shareholders for 2022 was RMB 28.106 million, an improvement from a loss of RMB 42.255 million in 2021[13]. - Total assets as of December 31, 2022, amounted to RMB 337.196 million, a decrease from RMB 347.595 million in 2021[13]. - Total liabilities increased to RMB 253.483 million in 2022, compared to RMB 237.236 million in 2021[13]. - The comprehensive gross profit was RMB 16,395,267, with a gross profit margin of 3.67%, significantly down from 9.57% in the previous year[38]. - Sales and distribution costs decreased by 39.17% to RMB 10,516,917, attributed to adjustments in the business model and reduced marketing expenses[39]. - Administrative expenses were RMB 26,971,894, a reduction of 14.28% from RMB 31,466,638 in the previous year, mainly due to decreased depreciation and bad debt losses[42]. - Research and development expenses dropped by 67.52% to RMB 1,136,489, primarily due to changes in the operating model of a subsidiary[43]. - Financing costs increased by 17.09% to RMB 6,401,517, driven by an increase in short-term borrowings to RMB 56,700,000 from RMB 47,400,000 in the previous year[44]. - The net loss attributable to owners for the year was RMB 28,106,065, with a loss per share of RMB 1.48, compared to RMB 42,255,043 and RMB 2.23 per share in 2021[45]. Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, indicating a diversified business model[6]. - The company has been focusing on the development of new products in the bio-composite fertilizer sector to enhance market competitiveness[6]. - The company plans to expand its elderly care services across the country, indicating a strategic growth initiative[6]. - The company acquired Shanghai Weidi Network Technology Co., Ltd., which has developed a Direct to Consumer (DTC) system platform, facilitating future online sales of health products and compound fertilizers[26]. - The company plans to expand its elderly health resource allocation business, including the sale of elderly food and health products, aiming to develop this segment into a profit growth point[30]. - The company will enhance market marketing management and adjust product structures based on market demand to improve market share[29]. - The company has strengthened safety and epidemic prevention measures in its elderly care services, ensuring stable operations during the COVID-19 pandemic[25]. - The company aims to transition some offline sales of health products and compound fertilizers to the DTC online platform as it matures[30]. - The company plans to enhance market management and adjust product structure based on market demand to increase market share in the compound fertilizer industry[67]. - The company will continue to expand its elderly health product offerings, including rental aids and elderly food sales, to create a new profit growth point[68]. Market Trends and Challenges - In the first half of 2022, the prices of raw materials for compound fertilizers continued to rise significantly due to global inflation and the Russia-Ukraine conflict, impacting production costs[22]. - The compound fertilizer industry is entering a transformation phase, with companies adjusting product structures to seek upgrades and higher competitive stages[29]. - The aging population in China reached 280 million, accounting for 19.8% of the total population, highlighting the potential growth in the elderly care service industry[68]. - The company is developing a Direct to Consumer (DTC) system platform to transition some elderly health products and compound fertilizers to online sales[68]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of its financial reporting, as stated by its board of directors[1]. - The board consists of 2 executive directors, 3 non-executive directors, and 3 independent non-executive directors, with a total of 9 members as per the company's articles of association[135]. - The audit committee held five meetings during the fiscal year and reviewed the financial performance for the year ending December 31, 2022[126]. - The company has implemented a comprehensive risk management and internal control system to ensure compliance with applicable laws and regulations[140]. - The company has arranged professional training for all directors and senior management regarding the GEM listing rules to mitigate legal risks[143]. - The independent non-executive directors have confirmed their independence according to GEM listing rules, ensuring compliance with governance standards[142]. - The company is committed to maintaining transparency and effective communication with shareholders, ensuring their opinions are conveyed to the board[136]. Environmental and Social Responsibility - The company is committed to sustainable development and has adopted policies to promote social and environmental sustainability[27]. - The group focuses on environmental protection and has implemented clean production practices[180]. - The group ensures that all solid waste is comprehensively utilized and treated according to regulations[183]. - The group adheres to national environmental standards for air, water, and noise pollution[184]. - The company has established a corporate social responsibility strategy centered on caring for employees, the environment, and society[179]. - The company has implemented a clean production audit since 2012, promoting energy saving and pollution reduction among employees[187]. Shareholder Information - The company issued a total of 199,500,000 new shares at a subscription price of HKD 0.25 per share, raising a net amount of HKD 49,225,000 for operational funding in elderly care services[50]. - Major shareholders include State-owned Assets Management with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei with 180,000,000 shares (9.50%) as of December 31, 2022[119]. - The company did not repurchase any shares during the fiscal year ending December 31, 2022[124]. - No new share option plans were approved during the fiscal year ending December 31, 2022[125]. - Shareholders holding at least 10% of the issued share capital can request a special general meeting[172]. - Shareholders with at least 5% of the issued shares can propose new resolutions for discussion at the annual general meeting[174].

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二二年度全年業績公佈 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公佈的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公佈的資料共同及個 別 ...

Financial Performance - For the nine months ended September 30, 2022, the group achieved a consolidated revenue of RMB 304,972,430, a decrease of 14.61% compared to RMB 357,140,151 for the same period last year[6] - The consolidated gross profit for the nine months ended September 30, 2022, was RMB 11,188,179, representing a significant decrease of 71.03% from RMB 38,625,967 in the previous year[6] - The loss attributable to equity holders for the nine months ended September 30, 2022, was RMB 21,627,090, compared to a profit of RMB 1,823,539 for the same period last year, resulting in a loss per share of RMB 1.142[6] - Revenue from fertilizer products and elderly care services for the nine months ended September 30, 2022, was RMB 304,972,430, down from RMB 357,140,151 in the previous year[9] - The group reported a pre-tax loss of RMB 21,852,487 for the nine months ended September 30, 2022, compared to a profit of RMB 1,993,104 in the previous year[7] - The total operating expenses and net losses for the nine months ended September 30, 2022, were RMB 2,905,191, compared to RMB 595,667 in the same period last year[7] - The comprehensive gross profit for the same period was RMB 11,188,179, reflecting a significant decrease of 71.03% from RMB 38,625,967 in 2021[31] - The operating comprehensive gross profit margin was 3.67%, down 7.15% from 10.82% in the previous year[31] - The sales and distribution costs decreased by 45.01% to RMB 9,368,063 from RMB 17,036,248 in 2021[31] - Research and administrative expenses increased by 19.72% to RMB 22,477,429 compared to RMB 18,774,490 in the previous year[31] - Financing costs surged by 189.21% to RMB 4,100,365 from RMB 1,417,792 in 2021[31] - Basic loss per share was RMB 1.142, while the previous year reported earnings per share of RMB 0.096[15] Corporate Governance - The board of directors does not recommend the payment of any dividend for the nine months ended September 30, 2022[6] - The company has not reported any new product developments or market expansion strategies during this period[6] - The company appointed Mr. Qin Wenhua as Co-CEO on September 6, 2022, with Ms. Sun Li transitioning from CEO to Co-CEO[45] - No competition or potential conflicts of interest were reported among the company's directors, supervisors, or management shareholders as of September 30, 2022[46] - The audit committee consists of three independent non-executive directors, with Mr. Li Xudong serving as the chairman due to his professional accounting qualifications and auditing experience[47] - No new share option plans were approved during the period ending September 30, 2022[48] - The company did not enter into any management contracts for overall business or any major business during the period ending September 30, 2022[49] - The board of directors believes that the company has complied with all provisions of the corporate governance code, except for the requirement that the roles of chairman and CEO should be separate[50] - Ms. Sun Li was appointed as co-CEO, while Mr. Qin Wenhua was also appointed as co-CEO, maintaining continuity and stability in company policies[50] - The company aims to enhance corporate governance transparency and independence in the near future[50] Market and Industry Insights - The aging population in China, with 264 million people aged 60 and above, presents significant growth potential for the elderly care services industry[36] - The company plans to enhance marketing management and adjust product structure to improve market share in the compound fertilizer sector[35] Shareholder Information - As of September 30, 2022, the company has a total of 300,000,000 shares held by each of the directors, accounting for 15.83% of the issued shares[37] - Major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%) as of September 30, 2022[41] - The company has not achieved the profit guarantee for SJKGC for the fiscal years 2017, 2018, and 2019, with net profits of approximately $2,922,000, $305,000, and $411,000 respectively, all below the guaranteed amount of $5,390,000[44][45] Reporting and Availability - The report will be available for at least seven days on the GEM website and the company's website[51]

Financial Performance - For the six months ended June 30, 2022, the group achieved a consolidated revenue of RMB 205,210,475, a decrease of 15.13% compared to RMB 241,786,926 for the same period last year[6] - The consolidated gross profit for the same period was RMB 10,370,957, representing a significant decrease of 63.05% from RMB 28,064,013 in the previous year[6] - The loss attributable to equity holders for the six months ended June 30, 2022, was RMB 13,248,062, compared to a profit of RMB 809,551 for the same period last year, resulting in a basic loss per share of RMB 0.699[6] - Total revenue for the six months ended June 30, 2022, was RMB 205,210,475, a decrease from RMB 241,786,926 in the same period of 2021, representing a decline of approximately 15%[13] - The company reported a net loss before tax of RMB (13,248) for the six months ended June 30, 2022, compared to a loss of RMB (1,876) in the same period of 2021[18] - The company reported a basic loss per share of RMB (13,248,062) for the six months ended June 30, 2022, compared to a profit of RMB 809,551 in the same period of 2021[19] Assets and Liabilities - Non-current assets as of June 30, 2022, totaled RMB 138,480,513, slightly down from RMB 138,846,665 as of December 31, 2021[8] - Current assets increased significantly to RMB 361,364,056 as of June 30, 2022, compared to RMB 208,748,747 as of December 31, 2021[8] - The total current liabilities amounted to RMB 363,481,875, significantly higher than RMB 192,023,885 in the previous year[10] - The total assets minus current liabilities stood at RMB 136,362,694, a decrease from RMB 155,571,527 in the previous year[10] - As of June 30, 2022, the total assets were approximately RMB 499,844,569, with total liabilities of RMB 363,481,875, leading to a debt-to-asset ratio of 0.79[37] Cash Flow and Financing - Operating cash flow for the six months ended June 30, 2022, was a net outflow of RMB 21,636,996, compared to a net outflow of RMB 17,966,948 in the same period of 2021[11] - The cash and bank balances decreased to RMB 5,204,067 at the end of the period, down from RMB 26,789,577 at the end of the previous year[11] - The company raised RMB 30,000,000 from short-term/long-term bank loans during the financing activities for the six months ended June 30, 2022[11] - Financing costs increased significantly to RMB 3,330,598 for the six months ended June 30, 2022, compared to RMB 735,141 in the same period last year[7] - The company incurred financing expenses of RMB 3,330,598 for the six months ended June 30, 2022, compared to RMB 735,141 in the same period of 2021[14] Expenses - Research and administrative expenses for the six months ended June 30, 2022, were RMB 12,242,150, down from RMB 14,279,494 in the previous year[7] - Sales and distribution costs decreased by 38.11% year-on-year to RMB 8,118,740, down from RMB 13,117,605 in the previous year[32] - R&D and administrative expenses were RMB 12,242,150, reflecting a year-on-year decrease of 14.27% from RMB 14,279,494[33] - Financing costs surged by 453.06% year-on-year to RMB 3,330,598, compared to RMB 735,141 in the same period last year[34] Shareholder Information - The company did not recommend the payment of any dividend for the six months ended June 30, 2022[6] - The company did not recommend an interim dividend for the six months ended June 30, 2022, compared to no dividend in the same period of 2021[28] - The major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%) [46] Business Operations - The company is involved in two main business areas: bio-composite fertilizers and elderly care services, with ongoing adjustments to product structure and sales management in response to market demand[29] - The company faced increased production costs for bio-composite fertilizers due to rising raw material prices and logistics costs, but successfully passed some of these costs onto customers[29] - The company plans to enhance marketing management and adjust product structure to improve market share in the compound fertilizer sector[41] - The aging population in China reached 264 million, accounting for 18.7% of the total population, indicating a growing demand for elder care services[42] - The company aims to develop its rental business for elderly aids, leveraging its management of multiple elder care institutions in Shanghai[42] Corporate Governance - The company has established an audit committee to oversee financial reporting and internal controls[53] - The board believes that the dual role of the chairperson and CEO held by Ms. Sun Li is in the best interest of the company for maintaining policy continuity and operational stability[59] - The company is actively seeking candidates for the CEO position to enhance corporate governance transparency and independence[59] - The company has complied with all provisions of the corporate governance code except for the separation of the roles of chairperson and CEO[59] - There were no arrangements that allowed directors or supervisors to profit from purchasing company shares during the review period[45] - The company has not entered into any management contracts for overall or major business operations during the first half of 2022[56] - The company did not approve any new share option plans during the period ending June 30, 2022 [55] - There were no securities transactions by directors that violated trading rules during the review period[57] Audit and Financial Reporting - The audit committee reviewed the interim results and report for the six months ending June 30, 2022 [54] - The company has not recognized any significant capital commitments not provided for in the financial statements as of June 30, 2022[26]

[Report Overview](index=1&type=section&id=Report%20Overview) This section provides an overview of the company's information, disclaimer, and a summary of its quarterly financial performance [Company Information and Disclaimer](index=1&type=section&id=Company%20Information%20and%20Disclaimer) This report for Tianjin TEDA Biomedical Engineering Co., Ltd.'s Q1 2022 emphasizes GEM market investment risks and director responsibility for accuracy - The GEM market is positioned for small and medium-sized companies with higher investment risks compared to main board companies, requiring investors to understand potential risks and consider carefully[2](index=2&type=chunk) - Company directors jointly and individually assume full responsibility for the report's accuracy, completeness, and absence of misleading or fraudulent content[3](index=3&type=chunk) [Quarterly Results Summary](index=3&type=section&id=Quarterly%20Results%20Summary) Q1 2022 saw significant year-on-year declines in turnover and gross profit, a shift from profit to loss, and a substantial increase in loss attributable to equity holders 2022 Q1 Key Financial Indicators Summary | Indicator | 2022 Q1 (RMB) | 2021 Q1 (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Consolidated Turnover | 89,195,530 | 124,407,625 | -28.30% | | Consolidated Gross Profit | 5,489,781 | 13,722,640 | -59.99% | | Loss attributable to equity holders of the Company | (6,043,544) | (165,625) | Loss widened | | Loss per share | 0.319 cents | 0.009 cents | Loss widened | - The Board of Directors does not recommend paying a dividend for the three months ended March 31, 2022[5](index=5&type=chunk) [Unaudited Quarterly Results](index=4&type=section&id=Unaudited%20Quarterly%20Results) This section presents the unaudited consolidated income statement and detailed notes on the financial statements for the quarter [Consolidated Income Statement](index=4&type=section&id=Consolidated%20Income%20Statement) In Q1 2022, the group experienced a significant year-on-year decline in revenue and gross profit, leading to a substantial increase in loss for the period 2022 Q1 Unaudited Consolidated Income Statement | Indicator | 2022 Q1 (RMB) | 2021 Q1 (RMB) | | :--- | :--- | :--- | | Revenue | 89,195,530 | 124,407,625 | | Cost of Sales | (83,705,749) | (110,684,985) | | **Gross Profit** | **5,489,781** | **13,722,640** | | Other income and losses, net | 26,569 | 140,814 | | Selling and distribution costs | (4,263,313) | (7,828,413) | | R&D and administrative expenses | (6,621,896) | (7,455,064) | | Finance costs | (742,591) | (73,225) | | Loss before tax | (6,111,450) | (1,493,248) | | Income tax | – | – | | **Loss for the period** | **(6,111,450)** | **(1,493,248)** | | Loss attributable to owners of the Company | (6,043,544) | (165,625) | | Non-controlling interests | (67,906) | (1,327,623) | | Loss per share – Basic (RMB) | (0.319) cents | (0.009) cents | [Notes to Financial Statements](index=5&type=section&id=Notes%20to%20Financial%20Statements) This section details the basis of financial statement preparation, accounting policies, revenue breakdown, income tax treatment, loss per share calculation, and dividend policy - Financial statements are prepared on a historical cost convention and in accordance with Hong Kong Financial Reporting Standards, on a going concern basis[7](index=7&type=chunk) - Q1 2022 fertilizer product revenue decreased year-on-year, while elderly care and healthcare services revenue significantly increased year-on-year[8](index=8&type=chunk) - Income tax expenses for Hong Kong and China were zero during the period due to no taxable income or business[10](index=10&type=chunk) - Basic loss per share for Q1 2022 was **RMB 0.319 cents**, a significant increase from **RMB 0.009 cents** in the prior year[13](index=13&type=chunk) - The Board of Directors does not recommend paying an interim dividend for Q1 2022[14](index=14&type=chunk) [Basis of Presentation and Accounting Policies](index=5&type=section&id=Basis%20of%20Presentation%20and%20Accounting%20Policies) Financial statements are prepared under historical cost convention, adhering to HKFRS and GEM Listing Rules, with no significant impact from new HKFRS applications - Financial statements are prepared under the historical cost convention and in accordance with Hong Kong Financial Reporting Standards, generally accepted accounting principles in Hong Kong, the Hong Kong Companies Ordinance, and the disclosure requirements of the GEM Listing Rules[7](index=7&type=chunk) - The application of new Hong Kong Financial Reporting Standards had no significant impact on the Group's unaudited operating results and financial position[7](index=7&type=chunk) [Revenue Analysis](index=5&type=section&id=Revenue%20Analysis) This section provides a breakdown of the Group's revenue by product category for the first quarter of 2022 and 2021 2022 Q1 Revenue Composition | Product Category | 2022 Q1 (RMB) | 2021 Q1 (RMB) | | :--- | :--- | :--- | | Fertilizer products | 89,086,907 | 124,379,590 | | Elderly care and healthcare services | 108,623 | 28,035 | [Income Tax](index=6&type=section&id=Income%20Tax) This section details the applicable income tax rates in China and Hong Kong, and reconciles the loss before tax to the period's tax expense - The statutory corporate income tax rate in China is **25%**, with high-tech enterprises (e.g., Guangdong Fulilong Compound Fertilizer Co., Ltd.) enjoying a preferential rate of **15%**[9](index=9&type=chunk) - Income tax expenses for Hong Kong and China were zero during the period due to no taxable income or business[10](index=10&type=chunk) Reconciliation of Income Tax Expense to Loss Before Income Tax Expense | Indicator | 2022 Q1 (RMB thousands) | 2021 Q1 (RMB thousands) | | :--- | :--- | :--- | | Loss before income tax expense | (6,111) | (1,493) | | Tax calculated at corporate income tax rate of 25% | (1,528) | (373) | | Tax rate difference | 253 | 67 | | Impact of tax loss calculation | 1,275 | 306 | | Tax expense for the period | – | – | [Loss Per Share](index=7&type=section&id=Loss%20Per%20Share) This section outlines the calculation of basic loss per share for the first quarter of 2022 and 2021 Basic Loss Per Share Calculation | Indicator | 2022 Q1 (RMB) | 2021 Q1 (RMB) | | :--- | :--- | :--- | | Loss for calculation of basic earnings per share | (6,043,544) | (165,625) | | Weighted average number of ordinary shares | 1,894,500,000 | 1,894,500,000 | | Basic loss per share | (0.319) cents | (0.009) cents | [Dividends](index=8&type=section&id=Dividends) The Board of Directors has not recommended any interim dividend for the three months ended March 31, 2022 - The Board of Directors does not recommend paying an interim dividend for the three months ended March 31, 2022[14](index=14&type=chunk) [Changes in Reserves](index=8&type=section&id=Changes%20in%20Reserves) The report includes a statement of changes in reserves, but the table format is unclear, making specific data interpretation difficult - The report contains a statement of changes in reserves, but the table content format is disorganized and difficult to interpret specific data[15](index=15&type=chunk) [Management Discussion and Analysis](index=9&type=section&id=Management%20Discussion%20and%20Analysis) This section provides management's perspective on the Group's business operations, financial performance, risk factors, and future strategic outlook [Business Review](index=9&type=section&id=Business%20Review) The Group operates in biological compound fertilizers and elderly care services, with compound fertilizers as its core, while brainwave detection business development is slow - The Group is currently involved in two major business areas: biological compound fertilizer business and elderly care and healthcare business[16](index=16&type=chunk) - The elderly care and healthcare business focuses on individuals with severe cognitive impairment, offering operational management, resource integration, supervision, and consulting services, alongside developing assistive device leasing[16](index=16&type=chunk) - The brainwave detection business is developing slowly, and market expansion still requires time[16](index=16&type=chunk) [Financial Review](index=9&type=section&id=Financial%20Review) In Q1 2022, the Group's turnover, gross profit, and gross profit margin all significantly declined, leading to a substantial increase in loss attributable to owners 2022 Q1 Financial Performance Review | Indicator | 2022 Q1 (RMB) | 2021 Q1 (RMB) | Year-on-Year Change | | :--- | :--- | :--- | :--- | | Consolidated Turnover | 89,195,530 | 124,407,625 | -28.30% | | Consolidated Gross Profit | 5,489,781 | 13,722,640 | -59.99% | | Consolidated Gross Profit Margin | 6.15% | 11.03% | -4.88% | | Loss attributable to owners of the Company | (6,043,544) | (165,625) | Loss widened | | Loss per share | 0.319 cents | 0.009 cents | Loss widened | [Pledged Assets and Contingent Liabilities](index=9&type=section&id=Pledged%20Assets%20and%20Contingent%20Liabilities) As of March 31, 2022, the Group's contingent liabilities for bank loan guarantees were zero RMB, a significant reduction from RMB 3,000,000 at December 31, 2021 - As of March 31, 2022, contingent liabilities were **RMB zero**, a significant decrease from **RMB 3,000,000** as of December 31, 2021[18](index=18&type=chunk) [Foreign Currency Risk](index=10&type=section&id=Foreign%20Currency%20Risk) The Group faces minimal foreign currency risk as all sales and payments are settled in RMB - The Group faces minimal foreign currency risk as all sales are domestic sales settled in RMB, and all payments to suppliers are also settled in RMB[19](index=19&type=chunk) [Treasury Policy](index=10&type=section&id=Treasury%20Policy) The Group's bank borrowings are denominated in RMB, typically renewed annually, with cash balances held in licensed Chinese banks - The Group's bank borrowings are denominated in RMB and generally renewed annually upon maturity[20](index=20&type=chunk) - Any cash balances are deposited in licensed banks in China[20](index=20&type=chunk) [Future Outlook](index=10&type=section&id=Future%20Outlook) The Group anticipates a recovery in the compound fertilizer market and plans to optimize product structure, while expanding elderly care services through a light-asset model - The rapid increase in raw material prices for compound fertilizers may have ended, with the market expected to gradually recover; the company will strengthen marketing, adjust product structure, and promote efficient, intelligent production[21](index=21&type=chunk) - China's aging population highlights the elderly care service industry as a "sunrise industry" with great potential; the Group will primarily adopt a light-asset operating model, enhance professional capabilities, and vigorously develop assistive device leasing services[22](index=22&type=chunk) [Directors, Supervisors and Major Shareholders' Interests](index=12&type=section&id=Directors%2C%20Supervisors%20and%20Major%20Shareholders%27%20Interests) This section details the shareholdings of directors, supervisors, and major shareholders, and confirms the absence of competing interests or share option schemes [Directors' and Supervisors' Interests in Shares](index=12&type=section&id=Directors%27%20and%20Supervisors%27%20Interests%20in%20Shares) As of March 31, 2022, Ms. Sun Li indirectly held 15.83% of the company's shares, with no other directors disclosing interests or share option arrangements - Ms. Sun Li holds a long position of **300,000,000 ordinary shares**, representing **15.83%** of the issued share capital, indirectly held through Shenzhen Xiangyong Investment Co., Ltd. and Dongguan Luye Fertilizer Co., Ltd[23](index=23&type=chunk) - Except for Ms. Sun Li, as of March 31, 2022, no other directors, supervisors, or senior executives of the Company held any interests in the securities, related shares, and debentures of the Company or its associated corporations that needed to be disclosed to the Company and the Stock Exchange[24](index=24&type=chunk) - During the review period, neither the Company, its subsidiaries, nor its holding company entered into any arrangements that would allow the Company's directors and supervisors, or their respective spouses or children under 18, to profit from purchasing the Company's shares[25](index=25&type=chunk) [Major Shareholders](index=13&type=section&id=Major%20Shareholders) This report lists major shareholders holding over 5% of the company's shares as of March 31, 2022 Major Shareholders' Shareholding (as of March 31, 2022) | Shareholder Name/Company | Capacity | Number of Ordinary Shares | Percentage of Issued Share Capital | | :--- | :--- | :--- | :--- | | Tianjin Economic-Technological Development Area State-owned Assets Management Co., Ltd. | Beneficial owner | 182,500,000 | 9.63% | | Shenzhen Xiangyong Investment Co., Ltd. | Beneficial owner | 180,000,000 | 9.50% | | Guangdong Jiamei Ecological Technology Co., Ltd. | Beneficial owner | 180,000,000 | 9.50% | | Dongguan Luye Fertilizer Co., Ltd. | Beneficial owner | 120,000,000 | 6.33% | - All shares are domestic shares[26](index=26&type=chunk) [Other Important Matters](index=14&type=section&id=Other%20Important%20Matters) This section covers the SJKGC profit guarantee, competing interests, audit committee activities, share option schemes, management contracts, and corporate governance practices [SJKGC Profit Guarantee Background and Status](index=14&type=section&id=SJKGC%20Profit%20Guarantee%20Background%20and%20Status) After acquiring SJKGC, the company faced unfulfilled profit guarantees for 2018 and 2019, leading to arbitration and revised settlement agreements - The Company acquired a **51% equity interest** in SJKGC in 2016, with SJK guaranteeing SJKGC's audited after-tax profit for each of the three fiscal years 2017, 2018, and 2019 would be no less than **USD 5,390,000**[28](index=28&type=chunk)[29](index=29&type=chunk) - The 2017 profit guarantee was not met, and SJK fulfilled its commitment by paying a cash dividend of **USD 2,750,000**[29](index=29&type=chunk) - The 2018 and 2019 profit guarantees were not met, and as of now, SJK has not paid the guaranteed cash dividends to the Company[30](index=30&type=chunk) - The Company initiated arbitration proceedings at the Hong Kong International Arbitration Centre on September 3, 2019, and revised the "Settlement Agreement" and related agreements in 2020 and 2021[30](index=30&type=chunk) [Competing Interests](index=15&type=section&id=Competing%20Interests) For the three months ended March 31, 2022, no directors, supervisors, or management shareholders had competing interests with the Group's business - For the three months ended March 31, 2022, no directors, supervisors, or management shareholders of the Company and their respective associates had or might have any competing interests with the Group's business, or any other conflicts of interest with the Group[31](index=31&type=chunk) [Audit Committee](index=16&type=section&id=Audit%20Committee) The Audit Committee, comprising three independent non-executive directors, reviews financial reporting, external audit, internal controls, and has reviewed the quarterly results - The Audit Committee comprises three independent non-executive directors: Mr. Li Xudong (Chairman), Mr. Wang Yongkang, and Ms. Gao Chun[32](index=32&type=chunk) - The committee's primary responsibilities include reviewing and overseeing the Group's financial reporting process, and examining the effectiveness of external audits, internal controls, and risk assessments[32](index=32&type=chunk) - The Audit Committee has reviewed the Group's first quarterly results and first quarterly report for the three months ended March 31, 2022[32](index=32&type=chunk) [Share Option Scheme](index=16&type=section&id=Share%20Option%20Scheme) No new share option schemes were approved by the company during the period ended March 31, 2022 - No new share option schemes were approved by the Company during the period ended March 31, 2022[33](index=33&type=chunk) [Management Contracts](index=16&type=section&id=Management%20Contracts) No management contracts for the overall business or any major business were entered into or existed during the period ended March 31, 2022 - No contracts concerning the management or administration of the Company's overall business or any major business were entered into or existed during the period ended March 31, 2022[34](index=34&type=chunk) [Purchase, Sale or Redemption of Securities](index=16&type=section&id=Purchase%2C%20Sale%20or%20Redemption%20of%20Securities) Neither the company nor its subsidiaries purchased, sold, or redeemed any of the company's shares during the review period - The Company did not redeem any of its shares during the review period; neither the Company nor any of its subsidiaries purchased, sold, or redeemed any of the Company's shares during the period ended March 31, 2022[35](index=35&type=chunk) [Corporate Governance Practices](index=17&type=section&id=Corporate%20Governance%20Practices) The Board and management are committed to complying with the GEM Listing Rules' Corporate Governance Code and believe full compliance was achieved during the review period - The Company's Board of Directors and management are consistently committed to implementing the provisions of the Corporate Governance Code contained in Appendix 15 of the GEM Listing Rules within the Group[36](index=36&type=chunk) - The Directors believe that the Company has complied with all Code provisions during the review period[36](index=36&type=chunk)